샘플 요청 목록

 카트 문의
시장보고서
상품코드
1731879

세계의 광견병 백신 시장

Rabies Vaccine
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 467 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 광견병 백신 시장은 2030년까지 16억 달러에 도달

2024년에 13억 달러로 추정되는 세계의 광견병 백신 시장은 2030년에는 16억 달러에 달하며, 분석 기간인 2024-2030년의 CAGR은 3.8%로 성장할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 닭 배아 세포 광견병 백신은 CAGR 4.6%를 기록하며, 분석 기간 종료시에는 7억 800만 달러에 달할 것으로 예측됩니다. 베로 세포 광견병 백신 부문의 성장률은 분석 기간 중 CAGR 3.9%로 추정됩니다.

미국 시장은 3억 4,770만 달러로 추정, 중국은 CAGR 7.2%로 성장 예측

미국의 광견병 백신 시장은 2024년에 3억 4,770만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR이 7.2%로, 2030년까지 3억 2,480만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.5%와 3.0%로 예측됩니다. 유럽에서는 독일이 CAGR 2.2%로 성장할 것으로 예측됩니다.

세계의 "광견병 백신" 시장 - 주요 동향과 촉진요인 정리

건강 위협이 계속되는 가운데, '광견병 백신" 시장이 전 세계에서 주목받는 이유는 무엇인가?

광견병은 아시아와 아프리카를 중심으로 매년 5만 9,000명 이상의 목숨을 앗아가는 가장 치명적이면서도 완전히 예방 가능한 질병 중 하나이며, 100% 백신으로 예방할 수 있음에도 불구하고 보고 부족, 의료 서비스 접근성 제한, 인식 부족으로 인해 충분한 예방접종이 이루어지지 않고 있습니다. 세계보건기구(WHO)와 GAVI 등 정부, 비정부기구, 국제보건기구가 2030년까지 개를 매개로 한 광견병으로 인한 인간 사망을 없애기 위한 노력을 확대함에 따라 세계 광견병 백신 시장이 주목받고 있습니다. 노출 전 예방약(PrEP)과 노출 후 예방약(PEP) 모두에 대한 수요가 증가하고 있으며, 특히 개에 물리는 빈도가 가장 높은 농촌 지역과 고위험군 사이에서 이러한 경향이 두드러지고 있습니다. 인식 개선 캠페인과 개에 대한 백신 접종 의무화는 감염률을 개선하고 있습니다. 또한 전 세계 여행 및 관광의 부활로 인해 광견병이 유행하는 지역을 방문하기 전에 PrEP를 필요로 하는 여행자가 증가하면서 새로운 수요가 창출되고 있습니다. 교육기관, 동물보호센터, 동물병원들은 지역 보호에 대한 역할을 인식하고 광견병 백신의 재고를 늘리는 경향이 있습니다. 더욱 광범위한 규모에서는 소외된 열대성 질병을 대상으로 한 공중보건 자금이 국가 광견병 대책 프로그램에 투입되어 인간용과 동물용 광견병 백신의 일관된 조달이 추진되고 있으며, COVID-19 이후 반려동물 사육이 증가하고 인수공통전염병 예방에 대한 관심이 높아진 것도 한 몫을 하고 있습니다. 공중보건의 우선순위로서 광견병 백신 접종에 대한 인지도를 높여 장기적인 시장 확대의 발판을 마련했습니다.

백신 기술의 혁신은 광견병 예방접종 프로그램을 어떻게 변화시킬 것인가?

제조업체들이 구식 신경조직 백신에서 정제된 닭 배아 세포 백신(PCECV)이나 인간 이배체 세포 백신(HDCV)과 같은 보다 진보된 세포배양 기반 백신으로 전환하고 있기 때문입니다. 이러한 새로운 백신은 면역원성이 개선되고, 부작용이 적으며, 투여량이 적어 최신 예방접종 스케줄에 더 쉽게 적응할 수 있습니다. 또한 노출 후 프로토콜에서 기존의 광견병 면역글로불린을 대체하거나 보조할 수 있는 속효성 단클론 항체 기반 생물제제에 대한 연구도 진행 중입니다. 또한 원격지 및 저자원 환경에서의 콜드체인 물류 문제를 해결하기 위해 내열성 백신 제제가 등장하고 있습니다. 피내 투여나 마이크로니들 패치와 같은 바늘을 사용하지 않는 전달 방법은 사용 편의성을 개선하고, 필요한 용량을 줄이며, 환자의 순응도를 높이기 위해 시도되고 있습니다. 모바일 앱과 블록체인을 통한 백신 추적 및 확인과 같은 디지털 헬스 혁신은 예방접종 기록을 간소화하고 분산형 예방접종 캠페인의 모니터링을 개선하고 있습니다. 또한 주요 제약사들은 더 적은 횟수의 주사로 장기간 면역력을 강화하는 보조제 기술에 투자하고 있습니다. 또한 야생동물용 경구용 미끼 백신과 같은 동물용 광견병 백신의 혁신은 가축의 반려동물 외의 다른 동물에 대한 방역 전략을 확대하고 있습니다. 이러한 기술 발전은 모두 광견병 예방접종의 안전성, 효과, 접근성을 향상시키고, 발병시 신속한 대응을 가능하게 하며, 예방적 건강관리의 범위를 넓히는 데 기여하고 있습니다.

인체 및 동물용 의약품의 각 분야에서 수요를 주도하는 최종사용자 부문은 무엇인가?

광견병 백신 시장 수요 역학은 인간 헬스케어, 수의학 서비스, 공중 보건 기관에 걸친 다양한 최종 사용 부문에 의해 크게 영향을 받습니다. 인간 건강관리의 경우, 병원, 여행 진료소, 농촌 보건소가 노출 후 백신의 주요 소비자이며, 공공 부문 입찰 및 WHO 인증 공급업체를 통한 조달이 증가하고 있습니다. 도시 거주자들도 여행과 직업적 위험 증가, 교육 및 홍보 활동으로 인해 노출 전 예방접종에 대한 관심이 증가하고 있습니다. 한편, 동물병원과 동물보호시설에서는 가정에서 기르는 반려동물과 가축, 동물원 동물의 예방접종에 백신이 사용되어 병행 시장이 견고한 성장세를 보이고 있습니다. 특히 반려동물 산업은 팬데믹 이후 크게 성장하고 있으며, 정기적인 수의사 진료와 반려동물 백신 접종이 동시에 증가하고 있습니다. 농업 및 축산 부문, 특히 광견병이 가축과 작업동물에 감염되는 국가에서는 예방 백신 접종에 대한 투자도 증가하고 있으며, OIE(세계동물보건기구)와 같은 국제기구의 지원을 받은 정부 보건 부문은 광견병이 유행하는 지역에서 개와 야생동물 감염원을 대상으로 집단 예방접종 캠페인을 전개하고 있습니다. 동물, 인간, 환경의 건강이 상호 연관되어 있음을 인식하는 원헬스(One Health) 프레임워크에 광견병 백신을 통합함으로써 다부문 협력과 자금 조달이 더욱 확대되고 있습니다. 또한 세계 보건 및 동물 복지와 관련된 NGO 수요는 백신이 충분히 공급되지 않는 지역에 백신을 배포하는 데 기여하고 있습니다. 이러한 다각적인 최종 용도 동향은 광견병 백신이 전 세계 인수공통전염병 퇴치를 위한 의료적 필요성과 전략적 수단으로서 광견병 백신의 중요성이 커지고 있음을 입증합니다.

광견병 백신 시장의 성장은 기술 발전, 공중 보건에 대한 노력, 소비자 행동 변화와 관련된 몇 가지 요인에 의해 주도될 것입니다.

광견병 백신 시장의 성장은 기술 발전, 최종사용자 요구의 진화, 의료 서비스 제공 모델의 변화와 관련된 몇 가지 요인에 의해 주도되고 있습니다. 주요 촉진요인 중 하나는 더 나은 안전성 프로파일과 간편한 투여 요법을 제공하고 집단 예방 접종 프로그램에 더 적합한 최신 세포배양 기반 백신으로 광범위하게 전환되고 있다는 점입니다. 또한 기술 혁신으로 인해 콜드체인에 의존하지 않는 백신과 용량 절감형 피내 투여가 가능해져 외딴 지역이나 의료 서비스가 부족한 지역에서의 백신 접근성이 크게 개선되었습니다. 특히 아시아와 아프리카에서는 정부 주도의개 집단 예방접종 캠페인이 확산되고 있으며, 인간용 및 동물용 광견병 백신의 대규모 조달이 활성화되고 있습니다. 반려동물 보유율 증가와 동물 의료 서비스에 대한 수요는 민간 부문의 백신 판매를 더욱 촉진하고 있으며, WHO의 'Zero by 30' 전략과 같은 세계 공중보건 구상의 영향으로 전국적인 광견병 퇴치 프로그램에 대한 정치적, 재정적 지원이 생겨나면서 백신 배포가 전년 대비 꾸준히 증가하고 있습니다. 배치가 전년 대비 지속적으로 증가하는 원동력이 되고 있습니다. 또한 특히 학교를 중심으로 한 교육 프로그램과 미디어 홍보를 통해 광견병의 위협에 대한 인식이 높아지면서 비발생 지역에서도 백신 접종에 대한 소비자 행동이 변화하고 있습니다. 의료 시스템의 조달 전략이 진화함에 따라 대량 구매, 민관 파트너십, 다른 의료 서비스와의 백신 대량 공급이 선호되어 유통을 간소화하고 비용 효율성이 향상되고 있습니다. 마지막으로 광견병 백신이 여행 권고 및 고용주 의무 건강검진에 포함됨에 따라 여행자, 주재원, 현장 근로자 사이에서 수요가 증가하고 있습니다. 이러한 다각적인 요인들이 세계 광견병 백신 시장의 지속적인 성장의 원동력이 되고 있으며, 소외된 열대 질병 퇴치에 있으며, 중요한 부문으로 자리매김하고 있습니다.

부문

제품 유형(닭 배아 세포 광견병 백신, 베로 세포 광견병 백신, HDCV(Human Diploid Cell Vaccine), 기타 제품 유형); 예방 유형(노출전 예방, 노출후 예방); 용도(인간, 동물); 최종사용자(병원, 동물병원, 기타 최종사용자)

조사 대상 기업의 예(주목 41사)

  • AIM Vaccine Co., Ltd.
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • Berna Biotech Pharma GmbH
  • Bharat Biotech International Ltd.
  • Boehringer Ingelheim GmbH
  • Cadila Pharmaceuticals Ltd.
  • Chiron Behring Vaccines Pvt. Ltd.
  • Elanco Animal Health Inc.
  • GlaxoSmithKline plc(GSK)
  • Indian Immunologicals Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • VBI Vaccines Inc.
  • Virbac S.A.
  • Yisheng Biopharma Co., Ltd.
  • Zoetis Inc.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수입원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

무료 업데이트 각국의 최종 리셋이 발표된 후, 7월에 무료 업데이트 버전을 고객님들께 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <gt; 중국 <gt; 멕시코 <gt; 캐나다 <gt;EU <gt; 일본 <gt; 인도 <gt; 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정을 적용하고 있습니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.06.09

Global Rabies Vaccine Market to Reach US$1.6 Billion by 2030

The global market for Rabies Vaccine estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Chick Embryo Cells Rabies Vaccine, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$708.0 Million by the end of the analysis period. Growth in the Vero Cell Rabies Vaccine segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$347.7 Million While China is Forecast to Grow at 7.2% CAGR

The Rabies Vaccine market in the U.S. is estimated at US$347.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$324.8 Million by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global “Rabies Vaccine” Market - Key Trends & Drivers Summarized

Why Is the Rabies Vaccine Market Gaining Global Attention Amid Persistent Health Threats?

Rabies continues to be one of the most fatal yet entirely preventable diseases, claiming over 59,000 lives globally each year-primarily in Asia and Africa. Despite being 100% vaccine-preventable, under-reporting, limited access to healthcare, and lack of awareness have historically hindered adequate immunization. The global rabies vaccine market is gaining increased attention as governments, non-governmental organizations, and international health agencies-such as the WHO and GAVI-scale up efforts to eliminate human deaths from dog-mediated rabies by 2030. Demand is growing for both pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), especially in rural and high-risk populations where dog bites are most common. Rising awareness campaigns and mandatory dog vaccination drives are improving coverage rates. Moreover, the resurgence of global travel and tourism has added another layer of demand, with travelers requiring PrEP before visiting rabies-endemic regions. Educational institutions, animal welfare centers, and veterinary clinics are increasingly stocking rabies vaccines, recognizing their role in community protection. On a broader scale, public health funding aimed at neglected tropical diseases is being channeled toward national rabies control programs, driving consistent procurement of both human and veterinary rabies vaccines. The increase in pet adoption and heightened focus on zoonotic disease prevention post-COVID-19 have also elevated the profile of rabies vaccination as a public health priority, setting the stage for long-term market expansion.

How Are Innovations in Vaccine Technology Transforming Rabies Immunization Programs?

The rabies vaccine landscape is witnessing a technological transformation as manufacturers shift from outdated nerve tissue vaccines to more advanced cell culture-based vaccines such as purified chick embryo cell vaccine (PCECV) and human diploid cell vaccine (HDCV). These newer vaccines offer improved immunogenicity, fewer adverse reactions, and require fewer doses, making them more compliant with modern immunization schedules. Research is also underway on monoclonal antibody-based biologics that could serve as faster-acting alternatives or adjuncts to traditional rabies immunoglobulins in post-exposure protocols. Additionally, thermostable vaccine formulations are emerging to address the challenge of cold chain logistics in remote and low-resource settings. Needle-free delivery methods, such as intradermal administration and micro-needle patches, are being trialed to improve ease of use, reduce dosage requirements, and enhance patient compliance. Digital health innovations-such as mobile apps and blockchain for vaccine tracking and verification-are streamlining immunization records and improving monitoring in decentralized vaccination campaigns. Leading pharmaceutical firms are also investing in adjuvant technologies to enhance long-lasting immunity with fewer injections. Moreover, innovations in veterinary rabies vaccines, such as oral bait vaccines for wild animals, are expanding control strategies beyond domestic pets. All these technological advances are converging to enhance the safety, efficacy, and accessibility of rabies immunization, enabling faster response times in outbreak situations and broadening the scope of preventive healthcare.

Which End-Use Segments Are Driving Demand Across Human and Veterinary Health Sectors?

The demand dynamics within the rabies vaccine market are being strongly influenced by diverse end-use sectors spanning human healthcare, veterinary services, and public health agencies. In human healthcare, hospitals, travel clinics, and rural health centers are leading consumers of post-exposure vaccines, with increasing procurement supported by public-sector tenders and WHO-prequalified suppliers. Urban populations are also showing increased interest in pre-exposure vaccination due to heightened travel, occupational risks, and educational outreach. Meanwhile, veterinary clinics and animal shelters represent a robust parallel market, where vaccines are used to immunize domestic pets, livestock, and zoo animals. The pet industry, in particular, has grown significantly post-pandemic, with a concurrent rise in routine veterinary visits and pet vaccinations. Agricultural and livestock sectors, particularly in countries where rabies affects cattle and working animals, are also investing more in prophylactic vaccination. Government health departments, supported by international organizations such as OIE (World Organisation for Animal Health), are increasingly deploying mass vaccination campaigns in endemic regions, targeting dogs and wildlife reservoirs. The integration of rabies vaccines in One Health frameworks-recognizing the interconnectedness of animal, human, and environmental health-is further expanding multi-sectoral collaboration and funding. Additionally, demand from NGOs involved in global health and animal welfare is contributing to vaccine distribution in underserved areas. Together, these multi-pronged end-use trends underscore the rising importance of rabies vaccines as both a medical necessity and a strategic tool in the global fight against zoonotic diseases.

The Growth in the Rabies Vaccine Market Is Driven by Several Factors Related to Technological Evolution, Public Health Initiatives, and Shifting Consumer Behavior

The growth in the rabies vaccine market is driven by several factors related to technological advancements, evolving end-user needs, and changes in healthcare delivery models. One key driver is the widespread transition to modern, cell culture-based vaccines that offer better safety profiles and simplified dosing regimens-making them more suitable for mass immunization programs. Technological innovation has also enabled cold chain-independent vaccines and dose-sparing intradermal delivery, significantly improving vaccine accessibility in remote and underserved regions. The increasing prevalence of government-led mass dog vaccination campaigns-especially in Asia and Africa-is stimulating large-scale procurement of both human and veterinary rabies vaccines. Rising pet ownership and demand for animal health services are further boosting vaccine sales in the private sector. The influence of global public health initiatives, such as the WHO’s “Zero by 30” strategy, is generating political and financial support for nationwide rabies control programs, driving consistent year-on-year growth in vaccine deployment. Additionally, greater awareness of the rabies threat, especially through school-based education programs and media outreach, is shifting consumer behavior toward preventive vaccination even in non-endemic regions. Evolving procurement strategies in the healthcare system-favoring bulk purchasing, public-private partnerships, and bundled delivery of vaccines with other healthcare services-are streamlining distribution and improving cost-efficiency. Lastly, the inclusion of rabies vaccines in travel advisories and employer-mandated health screenings is expanding demand among travelers, expatriates, and field workers. Together, these multidimensional factors are powering sustained growth in the global rabies vaccine market, positioning it as a critical segment in the fight against neglected tropical diseases.

SCOPE OF STUDY:

The report analyzes the Rabies Vaccine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine, Other Product Types); Prophylaxis Type (Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis); Application (Human, Animal); End-User (Hospitals, Veterinary Clinics, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AIM Vaccine Co., Ltd.
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • Berna Biotech Pharma GmbH
  • Bharat Biotech International Ltd.
  • Boehringer Ingelheim GmbH
  • Cadila Pharmaceuticals Ltd.
  • Chiron Behring Vaccines Pvt. Ltd.
  • Elanco Animal Health Inc.
  • GlaxoSmithKline plc (GSK)
  • Indian Immunologicals Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • VBI Vaccines Inc.
  • Virbac S.A.
  • Yisheng Biopharma Co., Ltd.
  • Zoetis Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Rabies Vaccine - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Rabies in Developing Regions Drives Demand for Preventive Vaccination
    • Growing Government-Led Mass Immunization Programs Strengthen Public Sector Procurement
    • Technological Advancements in Cell Culture-Based Vaccines Improve Safety and Efficacy Profiles
    • WHO Initiatives for Zero Human Rabies Deaths by 2030 Spur International Funding and Adoption
    • Expansion of Veterinary Rabies Vaccination Programs Boosts Animal Health Market Penetration
    • Cold Chain Infrastructure Development Improves Vaccine Reach in Remote Areas
    • Increased Partnerships Between Global Health Agencies and Manufacturers Accelerate Access
    • Growing Awareness of Pre-Exposure Prophylaxis Among Travelers Expands Target Market
    • Private Sector Entry into Animal and Human Vaccine Manufacturing Drives Competitive Landscape
    • Emergence of Single-Dose Regimens Enhances Convenience and Compliance in Endemic Regions
    • R&D in Recombinant Rabies Vaccines Opens New Avenues for Innovation
    • Government Regulation of Pet Ownership and Stray Animal Control Encourages Domestic Vaccine Uptake
    • Public Health Campaigns Highlighting Rabies Risks Strengthen Surveillance and Reporting
    • Investment in Veterinary Clinics and Pet Care Ecosystems Supports Preventive Inoculation
    • Regional Manufacturing Capabilities Improve Affordability and Supply Chain Stability
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rabies Vaccine Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rabies Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Rabies Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chick Embryo Cells Rabies Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chick Embryo Cells Rabies Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chick Embryo Cells Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Vero Cell Rabies Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Vero Cell Rabies Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Vero Cell Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Human Diploid Cell Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Human Diploid Cell Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Human Diploid Cell Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Veterinary Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Veterinary Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Veterinary Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Pre-Exposure Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Pre-Exposure Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Pre-Exposure Prophylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Post-Exposure Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Post-Exposure Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Post-Exposure Prophylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Human by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Animal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Animal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Animal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • JAPAN
    • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • CHINA
    • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • EUROPE
    • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Rabies Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • FRANCE
    • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 101: France Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • GERMANY
    • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 137: UK Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 140: UK Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 143: UK Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 149: Spain Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Spain Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Spain 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Spain 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 161: Russia Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Russia Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Russia 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Russia Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Russia 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Europe Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Europe 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Europe 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 186: Asia-Pacific Historic Review for Rabies Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Asia-Pacific 15-Year Perspective for Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Asia-Pacific 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 200: Australia Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Australia Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Australia 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Australia Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Australia 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • INDIA
    • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 212: India Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: India Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: India 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 215: India Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: India Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: India 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 218: India Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 224: South Korea Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: South Korea Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: South Korea 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: South Korea Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: South Korea 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Asia-Pacific Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 248: Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 249: Latin America Historic Review for Rabies Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Latin America 15-Year Perspective for Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Latin America Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Latin America 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 263: Argentina Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Argentina Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Argentina 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Argentina Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Argentina 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 275: Brazil Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Brazil Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Brazil 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Brazil Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Brazil 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 287: Mexico Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Mexico Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Mexico 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Mexico Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Mexico 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Latin America Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Latin America 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Latin America 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 311: Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 312: Middle East Historic Review for Rabies Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Middle East 15-Year Perspective for Rabies Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Middle East Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Middle East 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 326: Iran Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Iran Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Iran 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Iran Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 331: Iran 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 338: Israel Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Israel Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 340: Israel 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Israel Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 343: Israel 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Saudi Arabia Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 352: Saudi Arabia 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 355: Saudi Arabia 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 362: UAE Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: UAE Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 364: UAE 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: UAE Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 367: UAE 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Rest of Middle East Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 376: Rest of Middle East 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Middle East 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030
  • AFRICA
    • Rabies Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 386: Africa Recent Past, Current & Future Analysis for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Africa Historic Review for Rabies Vaccine by Product Type - Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 388: Africa 15-Year Perspective for Rabies Vaccine by Product Type - Percentage Breakdown of Value Sales for Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Africa Historic Review for Rabies Vaccine by End-user - Veterinary Clinics, Other End-Users and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 391: Africa 15-Year Perspective for Rabies Vaccine by End-user - Percentage Breakdown of Value Sales for Veterinary Clinics, Other End-Users and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Rabies Vaccine by Prophylaxis Type - Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Rabies Vaccine by Prophylaxis Type - Percentage Breakdown of Value Sales for Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis for the Years 2015, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Rabies Vaccine by Application - Human and Animal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Rabies Vaccine by Application - Human and Animal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Rabies Vaccine by Application - Percentage Breakdown of Value Sales for Human and Animal for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제